Financial News
Press Releases about Immunovant Inc
Roivant Provides Update on Graves’ Disease Development Program
September 09, 2024
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From Roivant Sciences
Via GlobeNewswire
Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
September 26, 2023
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Topics
Death
Exposures
Death
Via NewMediaWire
Topics
Lawsuit
Via NewMediaWire
Topics
Lawsuit
Via NewMediaWire
Topics
Lawsuit
Via NewMediaWire
Topics
Lawsuit
Via NewMediaWire
Topics
Lawsuit
Via NewMediaWire
Topics
Lawsuit
NASDAQ:IMVT Investor Notice: Deadline on April 20, 2021 in Lawsuit Against Immunovant, Inc.
April 07, 2021
Via SBWire
Topics
Lawsuit
Via NewMediaWire
Topics
Lawsuit
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.